UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

P0091 A pilot study of low-dose capecitabine plus trastuzumab as first-line treatment in patients aged 75 years or older with HER2-positive advanced gastric cancer

European journal of cancer (1990), 2015-07, Vol.51, p.e18-e18

2015

Volltextzugriff (PDF)

P208 A pilot study of low-dose capecitabine plus trastuzumab as first-line treatment for patients older than 75 years with HER2-positive advanced gastric cancer

European journal of cancer (1990), 2014-05, Vol.50, p.e67-e67

2014

Volltextzugriff (PDF)

AOSOP5 A PHASE 2 TRIAL OF SALVAGE TREATMENT WITH GEMCITABINE AND S-1 COMBINATION IN HEAVILY PRETREATED PATIENTS WITH METASTATIC COLORECTAL CANCER

European journal of cancer (1990), 2013-03, Vol.49, p.S3-S3

2013

Volltextzugriff (PDF)

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

Annals of oncology, 2020-10, Vol.31 (10), p.1397-1404

2020

Volltextzugriff (PDF)

3079 POSTER 3-day Aprepitant Plus Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving Cisplatin-based Chemotherapy

European journal of cancer (1990), 2011, Vol.47, p.S245-S245

2011

Volltextzugriff (PDF)

6583 POSTER Phase I Dose-finding Study of Epirubicin, Oxaliplatin and S-1 (EOS) in Patients With Previously Untreated Advanced Gastric Cancer (AGC)

European journal of cancer (1990), 2011, Vol.47, p.S466-S466

2011

Volltextzugriff (PDF)

141P Microsatellite instability and its relationship with systemic inflammation as prognostic factors in localised colorectal cancer

Annals of oncology, 2023-10, Vol.34, p.S237-S237

2023

Volltextzugriff (PDF)

Array-based comparative genomic hybridization and copy number variation in cancer research

Cytogenetic and genome research, 2006-11, Vol.115 (3-4), p.262-272

2006

Volltextzugriff (PDF)

Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer

Annals of oncology, 2019-11, Vol.30, p.ix166

2019

Volltextzugriff (PDF)

OA05.04 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S54

2023

Volltextzugriff (PDF)

P1.16-01 Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S126

2022

Volltextzugriff (PDF)

EP08.02-025 Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S408-S409

2022

Volltextzugriff (PDF)

1333P A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations

Annals of oncology, 2023-10, Vol.34, p.S769-S769

2023

Volltextzugriff (PDF)

1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose

Journal of thoracic oncology, 2016-04, Vol.11 (4 Suppl), p.S113

2016

Volltextzugriff (PDF)

CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study

Annals of oncology, 2017-11, Vol.28 (suppl_10), p.x189-x189

2017

Volltextzugriff (PDF)

LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial

Annals of oncology, 2022-09, Vol.33, p.S1423

2022

Volltextzugriff (PDF)

P86.12 Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S677-S678

2021

Volltextzugriff (PDF)

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC

Annals of oncology, 2019-11, Vol.30, p.ix157-ix158

2019

Volltextzugriff (PDF)

1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC

Annals of oncology, 2020-09, Vol.31, p.S813-S813

2020

Volltextzugriff (PDF)

P38 Phase 1 dose-finding study of epirubicin, oxaliplatin, and S-1 in patients with previously untreated advanced gastric cancer

European journal of cancer supplements, 2011, Vol.9 (1), p.15-16

2011

Volltextzugriff (PDF)

Analysis of plant and fruit growth and yield under a micro sap flow sensor automated irrigation in substrate hydroponics for tomato cultivation

Acta horticulturae, 2020-11 (1296), p.805-814

2020

Volltextzugriff (PDF)

JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results

Annals of oncology, 2018-10, Vol.29, p.viii542-viii542

2018

Volltextzugriff (PDF)

Osimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset

Annals of oncology, 2017-11, Vol.28, p.x190-x190

2017

Volltextzugriff (PDF)

P3.05-010 NOTCH 1 and NOTCH 3 Expressions for Early Stage of Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S2294-S2294

2017

Volltextzugriff (PDF)

Prognostic significance of cachexia score assessed by CT in male patients with small cell lung cancer

European journal of cancer care, 2018-01, Vol.27 (1), p.e12695-n/a

2018

Volltextzugriff (PDF)

1 – 25 von 196

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(178)
Mit Volltextzugriff
(177)

Publikationsform

Artikel
(191)
Tagungsberichte
(5)

Sprache

Englisch
(182)
Japanisch
(14)
Koreanisch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(70)
Life Sciences & Biomedicine
(58)
Humans
(27)
Biological And Medical Sciences
(21)
Biochemistry & Molecular Biology
(17)
Female
(16)
Animals
(15)
Hematology, Oncology And Palliative Medicine
(15)
Male
(15)
Fundamental And Applied Biological Sciences. Psychology
(14)
Biotechnology & Applied Microbiology
(13)
Cell Biology
(13)
Biotechnology
(12)
Mice
(12)
Gastroenterology And Hepatology
(10)
Middle Aged
(10)
Oncology
(10)
Technology
(10)
생물학
(10)
Aged
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

P0091 A pilot study of low-dose capecitabine plus trastuzumab as first-line treatment in patients aged 75 years or older with HER2-positive advanced gastric cancer

P208 A pilot study of low-dose capecitabine plus trastuzumab as first-line treatment for patients older than 75 years with HER2-positive advanced gastric cancer

AOSOP5 A PHASE 2 TRIAL OF SALVAGE TREATMENT WITH GEMCITABINE AND S-1 COMBINATION IN HEAVILY PRETREATED PATIENTS WITH METASTATIC COLORECTAL CANCER

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

3079 POSTER 3-day Aprepitant Plus Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving Cisplatin-based Chemotherapy

6583 POSTER Phase I Dose-finding Study of Epirubicin, Oxaliplatin and S-1 (EOS) in Patients With Previously Untreated Advanced Gastric Cancer (AGC)

141P Microsatellite instability and its relationship with systemic inflammation as prognostic factors in localised colorectal cancer

Array-based comparative genomic hybridization and copy number variation in cancer research

Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer

OA05.04 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study

P1.16-01 Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

EP08.02-025 Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial

1333P A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations

1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose

CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study

LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial

P86.12 Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC

1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC

P38 Phase 1 dose-finding study of epirubicin, oxaliplatin, and S-1 in patients with previously untreated advanced gastric cancer

Analysis of plant and fruit growth and yield under a micro sap flow sensor automated irrigation in substrate hydroponics for tomato cultivation

JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results

Osimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset

P3.05-010 NOTCH 1 and NOTCH 3 Expressions for Early Stage of Non-Small Cell Lung Cancer

Prognostic significance of cachexia score assessed by CT in male patients with small cell lung cancer

Suchergebnisse filtern